Novax is implementing several management changes. Effective today, Jonas Hedman takes on the role of Interim CEO of Novax. At the same time, Josef Bexell takes the step to become Group CEO of Novax’s portfolio company Bond Health Group, while Pär Warnström is leaving Novax for an external CEO position.
Jonas Hedman has been appointed Interim CEO of Novax. He will serve in this role until a permanent CEO has been recruited, a process that is now underway. Jonas has played a central role as Senior Director at Novax since September 2016, with a long background in corporate finance from Catella, Handelsbanken, and KPMG. Today, Jonas represents Novax as Chairman of Personalkollen and as Board Member of Apohem, Medovia, Bond Health Group, RCO, and Voyado.
Josef Bexell becomes Group CEO of Bond Health Group. Since 2014, Josef has worked at Novax with a focus on health investments. He is now moving from his role as investor and Chairman to take on the position of Group CEO of Bond Health Group. Bond is Novax’s commitment to building a Nordic leader in preventive health, with operations in training (STC), aggregated wellness services for consumers (Bruce Studios), and corporate wellness services (Aspire).
Pär Warnström departs for an external CEO role. Pär joined Novax in 2019 and has been responsible for investments in the Future of Food segment. He has been a highly appreciated colleague and instrumental in Novax’s investments in food, including the launch of ingredient group Ingå Group. Pär will remain at Novax until the end of the year to ensure a smooth transition.
To continue developing and growing the two platforms Bond Health Group and Ingå Group, Ida Linderbrandt and William Appelgren have been appointed as Investment Managers. At the same time, recruitment processes are ongoing to hire a new CEO and a new Senior Director, with the aim of supporting Novax’s planned future growth.
“I am convinced that the new organization will deliver on our strategy, and I look forward to continuing my work with the Novax team,” says Camilla Wideroth, Chair of the Board of Novax.
Novax’s mission is to build significant new companies for Axel Johnson – a focus that has been further clarified during the year through the decision to invest in fewer but larger and more mature companies going forward. The first half of 2025 has been characterized by a high level of activity, including investments in Bond Health Group, OneLab, and Ingå Group, as well as divestments such as Filippa K, Apoex Privat Vård, and a significant shareholding in the fast-growing SaaS company Voyado.
